Matt Devalaraja

7 papers receiving 582 citations

Matt Devalaraja's Hit Papers

IL-6 inhibition with ziltivekimab in patients at high atherosclerotic risk (RESCUE): a double-blind, randomised, placebo-controlled, phase 2 trial 2021 · 475 citations
4750+1+3Years since publication100200300400

Peers

Matt Devalaraja
Comparison fields: 5 of 64
  • Nephrology 53
  • Immunology 157
  • Hematology 70
  • Cardiology and Cardiovascular Medicine 110
  • Genetics 33
Replace Milana Ivkovic with:
Milana Ivkovic Denmark
Ryan Melchior United States
Wendy M. Mol Netherlands
Abdalrahman Zarzour United States
Arne Yndestad Norway
S. Osanto Netherlands
Wenche Jy United States
Masafumi Sugiyama Japan
Yuka Jiuchi Japan
Liyan Wan China
Matt Devalaraja relative to Milana Ivkovic Denmark Milana Ivkovic's profile →
Citations per field
00.5×4.1×
Milana Ivkovic · 1×
Citations per year

Countries citing papers authored by Matt Devalaraja

Since Specialization
Citations

This map shows the geographic impact of Matt Devalaraja's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Matt Devalaraja with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Matt Devalaraja more than expected).

Fields of papers citing papers by Matt Devalaraja

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Matt Devalaraja. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Matt Devalaraja. The network helps show where Matt Devalaraja may publish in the future.

Co-authors

The 25 scholars most cited alongside Matt Devalaraja, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Matt Devalaraja Line = papers co-authored together Matt Devalaraja links everyone, so they are left out of the graph.

All Works

8 of 8 papers shown
#Work
1
IL-6 inhibition with ziltivekimab in patients at high atherosclerotic risk (RESCUE): a double-blind, randomised, placebo-controlled, phase 2 trial
Hit paper breakdown →
2021475
2 202058
3 201921
4 201518
5 20209
6 20227
7 20232
8 20190

About Matt Devalaraja

Matt Devalaraja is a scholar working on Nephrology, Hematology, Molecular Biology, Dermatology and Cardiology and Cardiovascular Medicine, having authored 8 papers that have together received 590 indexed citations. Recurring topics across this work include Erythropoietin and Anemia Treatment (2 papers), Dialysis and Renal Disease Management (2 papers), Gut microbiota and health (1 paper), Allergic Rhinitis and Sensitization (1 paper), Sodium Intake and Health (1 paper), Digestive system and related health (1 paper), Asthma and respiratory diseases (1 paper) and Probiotics and Fermented Foods (1 paper). The work is most often cited by research in Nephrology (53 citations), Immunology (157 citations), Hematology (70 citations), Cardiology and Cardiovascular Medicine (110 citations) and Genetics (33 citations). Matt Devalaraja has collaborated with scholars based in United States, Italy and United Kingdom. Frequent co-authors include Larry Lo, Michael Davidson, Pablo E. Pérgola, Douglas Kling, Florian M.M. Baeres, Mads D.M. Engelmann, Milana Ivkovic, Paul M. Ridker, Peter Libby and G. Kees Hovingh. Their work appears in journals such as Journal of the American Society of Nephrology, Inflammatory Bowel Diseases, The Lancet, Journal of the American Heart Association and Nephrology Dialysis Transplantation.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact